The line-up is revealed to include Merck & Co and J&J itself.
ApexOnco Front Page
Recent articles
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
Bristol will test the bispecific in two new lung indications.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
A phase 1 study of OKI-219 reads out imminently.
After Genmab’s exit two more ADCs enter human trials.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
A new phase 3, Manifest-3, will start in April to support US filing.
